Erschienen in:
13.03.2023 | Brief Report
A case of complete recovery in a hypereosinophilic dermatitis patient with dupilumab
verfasst von:
Xiaoyun Jiang, Jun Ye, Xia Wu, Jiang Zhu, Siji Chen, Hao Cheng
Erschienen in:
Inflammation Research
|
Ausgabe 4/2023
Einloggen, um Zugang zu erhalten
Abstract
Background
Hypereosinophilic dermatitis (HED) is a subtype of hypereosinophilic syndrome (HES). Glucocorticoids are preferred for treatment but carry substantial side effect profiles. Symptoms of HED may recur after systemic glucocorticoid tapering. As an interleukin-4 receptor (IL-4Rα) monoclonal antibody targeting interleukin-4 (IL-4) and interleukin-13 (IL-13), dupilumab might be an efficacious adjuvant therapy for HED.
Method
We report a young male diagnosed with HED who suffered from erythematous papules with pruritus for over five years. Once reducing the dosage of glucocorticoid was, his skin lesions relapsed.
Results
After using dupilumab, the patient’s condition significantly improved with the glucocorticoid dosing decreased successfully.
Conclusion
In conclusion, we report a new application of dupilumab in HED patients, especially with difficulties in reducing the glucocorticoid dose.